Vera Therapeutics, Inc. (VERA)

Market Cap	2.22B
Revenue (ttm)	n/a
Net Income (ttm)	-107.85M
Shares Out	54.83M
EPS (ttm)	-2.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	465,116
Open	37.62
Previous Close	37.51
Day's Range	37.07 - 40.76
52-Week Range	9.24 - 50.78
Beta	0.99
Analysts	Strong Buy
Price Target	51.75 (+27.68%)
Earnings Date	Nov 7, 2024

About VERA

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was for...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 14, 2021
• Employees: 51
• Stock Exchange: NASDAQ
• Ticker Symbol: VERA
• Website: https://veratx.com

Analyst Forecast

According to 8 analysts, the average rating for VERA stock is "Strong Buy." The 12-month stock price forecast is $51.75, which is an increase of 27.68% from the latest price.

Price Target

$51.75

(27.68% upside)

Analyst Consensus: Strong Buy